Myocardial Metabolic Flux in Pulmonary Arterial Hypertension

NCT07737522 · Not yet recruiting

Last updated 2026-09-22

This clinical trial is testing how a GLP-1 agonist affects heart muscle energy metabolism in people with pulmonary arterial hypertension.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design open-label (no blinding) basic-science study

Participants 32 people Planned (estimated).

Who can join Ages 18–85 · all sexes

Timeline Started 2026-10 · est. completion 2029-04

What this study is testing ClinicalTrials.gov NCT07737522 ↗

Description as written by the study sponsor.

The rationale for this study is that GLP-1 agonist treatment is likely to influence myocardial substrate utilisation, changing the predominant source of metabolic energy within the heart to a more energetically efficient form. This is represented by a surrogate for improved mitochondrial efficiency with reduction in myocardial lactate levels (produced by inefficient myocardial glycolysis, prevalent in the ventricles of patients with pulmonary hypertension), which can be measured by 31P-magnetic resonance spectroscopy (31P-MRS).

Treatments tested

GLP-1 agonist Drug

Semaglutide

Main thing measured	Change in the phosphocreatine-to-adenosine triphosphate (31PCr/ATP) ratio between baseline and follow up in response to treatment with GLP-1 agonist
Sponsor	Imperial College London
Conditions studied	Pulmonary Arterial Hypertension
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07737522 ↗